Litcius/Paper detail

Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide

Lili Wu, Anqi Zheng, Yangming Tang, Xiaoyun Wang, Gao Yue, Wenwen Lei, Guizhen Wu, Qihui Wang, George F. Gao

2023hLife10 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakFusionPeptideChemistryMedicineBiochemistryInternal medicinePhilosophyLinguisticsOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesComputational Drug Discovery Methods
Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide | Litcius